Abstract
sequencing from both directions using the Dye Terminator
In this study we used RT-PCR and an enzyme Cycle Sequencing kit (Perkin Elmer).
immunoassay to detect viral RNA and antiviral antibodies (anti-E2) respectively, in sera of patients treated with haemodialysis (HD) or continuous ambulatory Phylogenetic analysis peritoneal dialysis (CAPD), as well as in sera of renal transplant ( RT ) recipients. We also searched for a Newly obtained sequences were compared with GBV-C/HGV possible association between these markers and liver sequences taken from the GenBank and reported earlier disease in GBV-C/HGV-infected patients. Information [6, 16 ] by means of the phylogenetic analysis using programs DNADIST and NEIGHBOR from the package PHYLIP, on the prevalence and characteristics of the GBVversion 3.5c ( Felsenstein, J. 1993. Department of Genetics, CIHGV infection in patients with renal failure should University of Washington, Seattle, USA). The evaluation of help us to minimize the risks of being infected both the significance of the grouping was assessed by the bootstrap for patients and staff and to prevent the spread of the analysis (100 replicates) using the program SEQBOOT. virus in the haemodialysis and transplantation units.
Detection of serological markers of GBV-C/HGV,

Subjects and methods
HCV, and HBV infections and ALT levels Patients
Serum samples were analysed for anti-HCV and HBsAg with enzyme-linked immunosorbent assay (Sorin Biomedica). The study involved 148 patients with end-stage kidney disease Antibodies to the envelope E2 protein of GBV-C/HGV treated at the department of nephrology, Essen University (anti-E2) were detected with the immunoassay kit 'AntiClinics. Thirty-one patients ( 22 male, aged 53±15 years) HGenv' kindly provided by Boehringer Mannheim. ALT were treated with haemodialysis ( HD group), 25 (16 male levels were determined on a multiparametric analyser using 47±15 years) with continuous ambulatory peritoneal dialysis the 'FCC method at 25°C. (CAPD group), and the remaining 92 (46 male 49±13 years) were subjected to renal transplantation ( RT group). Patients
Statistical analysis
who underwent renal transplantation were excluded from HD and CAPD groups. The patients had been on haemodiaResults were analysed with the chi-square test for categorical lysis and peritoneal dialysis for 2-252 months (median 25) variables and by the Mann-Whitney test for non-parametric and for 6-288 months (median 38) respectively. The time of qualitative data. P values of <0.05 were considered as a follow-up after renal transplantation varied between 1 and significant difference between groups. 204 months (median 50 ). The renal graft recipients continuously received immunosuppressive therapy consisting of prednisolone and azathioprine with or without cyclosporin.
Alanine aminotransferase (ALT ) levels were determined at Results monthly intervals. Additionally, two control groups comprising randomly chosen 128 multiple-organ donors and 368 Table 1 demonstrates the prevalence of GBV-C/HGV, volunteer blood donors were enrolled in the study.
HCV, and HBV markers in three groups of patients with renal failure. A statistical trend was noted for a RT-PCR and nucleotide sequencing higher rate of the GBV-C/HGV RNA detection in HD (9.7%) and RT ( 15.2%) patients in comparison with Serum samples were tested for HCV RNA by 'Amplicor' ( Roche Diagnostic System). GBV-C/HGV RNA was deter-organ donors (5.5%) (P=0.056; see note to Table 1 ). mined by RT-PCR as described earlier [16 ] with a few However, upon a comparison of the GBV-C/HGV modifications. RNA was extracted from 140 ml of serum with RNA frequencies in each of these patients groups with the QIAamp Viral RNA Kit (QIAGEN ) and was converted that among donors, only the difference between GBVto the complementary DNA (cDNA) with an antisense pri-C/HGV RNA prevalence in RT patients (15.2%) and mer ( YK-877 5∞-ACCGACACCTTAGATCCCCAGCCC). in organ donors (5.5%) was found to be significant Reverse-transcribed cDNA was subjected to the first round (P=0.028). Anti-E2 antibodies were detected with tion and three patients had both GBVC/HGV RNA Kekule, unpublished ). PCR fragments were gel purified with QIAquick gel extraction kit (Qiagen) and subjected to direct and HBsAg. Demographic, biochemical, and virological features of serum ALT levels ( 23 IU/l for males and 19 IU/l for females), in any patients with or without GBVwere compared between patients who were positive for GBV-C/HGV RNA in the serum and those who were C/HGV RNA. not ( Table 2 ). There were no significant differences in sex, age, prevalence of HCV RNA, anti-HCV, HBsAg,
Discussion
ALT levels, or history of blood transfusions between these groups. It should be noted, however, that a history of blood transfusions was reported by all At present only two methods to detect markers of GBV-C/HGV infection are available. One is RT-PCR, patients with GBV-C/HGV RNA. Time on haemodialysis was longer in patients infected with GBV-C/HGV which detects viral RNA in serum, and therefore is used for identification of acute and chronic infections. (median 68; range 25-138 months) compared to noninfected patients (median 23; range 2-288 months). Another, is the serological enzyme immunoassay (ELISA) for antibodies to the E2 protein of viral The difference was statistically significant (P<0.05). Similar analysis for patients with and without anti-E2 particles. These antibodies are indicators of a past GBV-C/HGV infection [14, 15] . Only the combination revealed no statistically significant differences for these groups with regard to the features studied (Table 2 ) . of these two techniques provide the most accurate assessment of the occurrence and prevalence of GBV-DNA amplificates from 14 GBV-C/HGV-positive patients were purified and subjected to direct sequen-C/HGV infection in a particular population group.
Using the RT-PCR we demonstrated a tendency cing. Phylogenetic analysis of the resulting sequences together with a set of sequences from the GenBank for a higher prevalence of GBV-C/HGV RNA in patients with renal failure (11.5%) and significantly was performed and the consensus phylogenetic tree is depicted in Figure 1 . This tree is characterized by higher rate of this RNA in RT patients (15.2%) than in a control group of organ donors (5.5%). These data, numerous branches. Bootstrap resampling, however, failed to reveal the segregation of these sequences into as well as the reported rates of GBV-C/HGV RNA in German blood donors (2.5-4.5%) [13] suggest that any major groups; bootstrap values obtained for all clades were always lower than the arbitrary cut-off patients with renal failure and in particularly RT patients are at increased risk of GBVC/HGV infection. value of 75%.
Biochemical and clinical investigations did not reveal None of the GBV-C/HGV RNA-positive patients and organ donors had anti-E2. This observation supany indications of liver disease, including the elevation and in immunosuppressed renal graft recipients. The resolution of the GBV-C/HGV infection in such patients might be a relatively rare event. Several recent publications provide some evidences supporting this hypothesis. First, Neilson et al., 1996 [17 ] , demonstrated higher prevalence of GBV-C/HGV RNA in patients who were profoundly immunosuppressed due to bone marrow transplantation. Masuko et al., 1996
[5] followed eight GBV-C/HGV RNA-positive haemodialysis patients for 7-14 years and demonstrated that only one of these patients had lost viral RNA after 10 years. On the other hand, the resolution rates of the GBV-C/HGV infection in non-immunosuppressed individuals seem to be much lower. Thus, Alter et al., 1997 [4] reported a clearance of GBV-C/HGV within 3 years in 3 of 8 subjects infected as a result of haemotransfusion. According to another paper [8], the persistence rate of the GBV-C/HGV infection acquired by blood transfusion by non-immunosuppressed patients was less than 40%; 8 of 22 infected subjects have lost viral RNA during the follow-up from 9 months to 8 years after transfusion. We were unable to identify any particular risk factor associated with the presence of anti-E2 in patients with renal failure. On the other hand, patients with the GBV-C/HGV RNA had been on haemodialysis for a significantly longer time and all of them had a history of blood transfusions compared to patients without viral RNA. This finding seems to supplement the recent data of Masuko et al.,1996 [5] , who demonstrated that some of 16 GBV-C/HGV RNA-positive HD patients were infected by haemotransfusions and some most probably by other means of transmission.
GBV-C/HGV RNA positivity rates in our groups of patients with renal failure are slightly higher than findings probably reflect the differences in GBVprototype isolates have the GenBank a.n U36380, U44402, and C/HGV prevalence in all these countries. One might U45966. Other sequences were taken from [6, 16 ] . also expect that the prevalence of GBV-C/HGV infection could vary significantly in different haemodialysis units even within the same country or geographical ports the notion [14,15] that anti-E2 are associated with a loss of viraemia. Thus GBV-C/HGV and HCV region due to variations in the transfusion practices and hygienic standards as had been shown for HCV infections are characterized by different virological and serological profiles; in the majority of HCV infected infection [18] . Non-optimal choice of PCR primers can be another reason for differences in the reported individuals viral RNA is present and persists in the presence of anti-HCV antibodies.
rates of the GBV-C/HGV RNA detection. Most recent findings have indicated that some parts of the GBVThe prevalence of anti-E2 in patients with renal failure and in organ and blood donors was almost the C/HGV genome are more variable than others [19 ] .
In our preliminary series of experiments [16 ] a set of same. On the first glance these results suggest the similar rates of exposure to GBV-C/HGV in all groups samples was tested for GBV-C/HGV RNA in parallel by PCR with primers from NS5, NS3, and 5∞-UTR of studied, and therefore contradict both our results and all available data [5,9-12] on the higher rates of GBV-viral genome, and not a single specimen out of more then 200 tested was found to be positive with primers C/HGV infection in patients with renal failure than in general population. One of the possible explanation of from 5∞-UTR or NS3 but negative with primers from NS5 region. this controversy might be that the establishment of the GBV-C/HGV infection and its chronic outcome are Upon a comparison of partial NS5 sequences from 14 patients from this study with 31 GBV-C/HGV probably more frequent in dialysis patients, generally characterized by impairment of their immune response, sequences taken from the GenBank and already pub-
